Teva Retains Top Slot In Generics/Biosimilar Rankings As Industry Faces US Pushback
Executive Summary
With Mylan snapping at its heels, Israel’s Teva managed to retain top slot in the latest Generics Bulletin rankings. Severe pricing and margin pressures in the US market made like difficult for generics companies in 2017, with eight of the top 20 firms reporting year on year sales declines.